APX 001

Drug Profile

APX 001

Latest Information Update: 19 Nov 2016

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Amplyx Pharmaceuticals
  • Class Antifungals; Small molecules
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Coccidioidomycosis; Candidiasis; Aspergillosis; Mycoses
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mycoses

Most Recent Events

  • 16 Nov 2016 APX 001 receives Orphan Drug status for Aspergillosis in USA
  • 16 Nov 2016 APX 001 receives Orphan Drug status for Candidiasis in USA
  • 16 Nov 2016 APX 001 receives Orphan Drug status for Coccidioidomycosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top